Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Replacement Statement re US Subsidiary Update

30 Oct 2025 11:30

RNS Number : 5342F
Belluscura PLC
30 October 2025
 

The following amendment has been made to the "Statement re US Subsidiary Chapter 7 Update" announcement released on 30/10/25 at 10.38 under RNS No 5186F.

 

The announcement was issued today, 30 October 2025, and confirms that on 29 October 2025 Belluscura LLC filed for Chapter 7 Bankruptcy under the U.S Bankruptcy Code.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

 

 

 

30 October 2025

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura LLC

 

Further to the notification of 28 October 2025, the Company confirms that on 29 October 2025 Belluscura LLC filed for Chapter 7 Bankruptcy under the U.S Bankruptcy Code.

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

 

SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

 

Dowgate Capital Limited

Joint Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Daniel Ingram (Corporate Finance)

Allenby Capital Ltd

Joint Broker

Tel: +44 (0)20 3328 5656

 

Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

 

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREAFEEDASSFFA
Date   Source Headline
13th Jan 202211:05 amRNSSecond Price Monitoring Extn
13th Jan 202211:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSExercise of Warrants and Total Voting Rights
29th Nov 20217:01 amRNSReimbursement approvals
29th Nov 20217:00 amRNSExercise of Warrants and Total Voting Rights
4th Nov 20217:00 amRNSTrading update
1st Nov 20217:00 amRNSThe Pulse: Healthcare Innovation Breakfast
25th Oct 20217:00 amRNSProduct wins Top Award at US Trade show
18th Oct 20217:00 amRNSNew US Distribution Agreement
8th Oct 20217:00 amRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSNotice of Results
31st Aug 20217:00 amRNSBelluscura supports rationale for wider oxygen use
27th Jul 20217:00 amRNSManufacturing and Distribution Agreement
13th Jul 20217:00 amRNSThird US Distribution Agreement
8th Jul 20217:00 amRNSThe US Centers for Medicare & Medicaid Services
5th Jul 20217:00 amRNSSecond US Distribution Agreement
30th Jun 202112:29 pmRNSResult of AGM
24th Jun 20211:13 pmRNSHolding(s) in Company
23rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:36 pmRNSPrice Monitoring Extension
23rd Jun 20212:05 pmRNSSecond Price Monitoring Extn
23rd Jun 20212:00 pmRNSPrice Monitoring Extension
23rd Jun 20217:00 amRNSFirst US Distribution Agreement
15th Jun 20217:00 amRNSSenior Management Appointment
9th Jun 20214:15 pmRNSExercise of Warrants
2nd Jun 20217:00 amRNSHolding(s) in Company
28th May 20217:00 amRNSAdmission to trading on AIM; First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.